


RET-IN-23

Cat. No.:	HY-153676
CAS No.:	2479961-46-9
Molecular Formula:	C ₂₈ H ₂₈ FN ₁₁
Molecular Weight:	537.59
Target:	RET
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	RET-IN-23 (compound 17) is a potent and orally active RET inhibitor with IC ₅₀ values of 1.32, 2.50, 6.54, 1.03, 1.47 nM for RET-WT, RET-CCDC6, RET-V804L, RET-V804M, RET-M918T, respectively. RET-IN-23 shows anti-tumor activity ^[1] .								
IC₅₀ & Target	IC ₅₀ : 1.32 nM (RET-WT); 2.50 nM (RET-CCDC6); 6.54 nM (RET-V804L); 1.03 nM (RET-V804M); 1.47 nM (RET-M918T) ^[1] .								
In Vivo	RET-IN-23 (5 mg/kg; p.o.) shows anti-tumor activity in mice ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>Balb/c-nu mouse (TT cell subcutaneous xenograft tumor)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>5 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>P.o.</td> </tr> <tr> <td>Result:</td> <td>Showed anti-tumor activity with T/C of 17.44%, TGI of 88.82%.</td> </tr> </table>	Animal Model:	Balb/c-nu mouse (TT cell subcutaneous xenograft tumor) ^[1]	Dosage:	5 mg/kg	Administration:	P.o.	Result:	Showed anti-tumor activity with T/C of 17.44%, TGI of 88.82%.
Animal Model:	Balb/c-nu mouse (TT cell subcutaneous xenograft tumor) ^[1]								
Dosage:	5 mg/kg								
Administration:	P.o.								
Result:	Showed anti-tumor activity with T/C of 17.44%, TGI of 88.82%.								

REFERENCES

[1]. ZhongHui Chen, et al. Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof. WO2020168939A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA